J&J units in pulmonary deals

Three Johnson & Johnson (NYSE:JNJ) units announced pulmonary and respiratory deals on Tuesday, including a licensing deal with Orexo AB (SSE:ORX) and the acquisition of RespiVert Ltd. (London, U.K.). J&J's Centocor Ortho Biotech Inc. unit did not disclose financial terms for its acquisition of RespiVert, which has two lead compounds in preclinical development for asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). RV-568 and RV-1088 are small molecule kinase inhibitors. Imperial Innovations, which held a 13.4% stake in RespiVert, said it will receive L9.5 million ($13.8 million) from the deal. ...